Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has provided an update.
EBR Systems, Inc. has received preliminary approval from the U.S. Centers for Medicare & Medicaid Services for the Transitional Pass-Through reimbursement scheme for its WiSE CRT System. This approval marks a significant milestone for EBR, as it will facilitate increased hospital adoption of their wireless cardiac pacing device in outpatient settings, providing a clear reimbursement pathway and potentially accelerating the system’s widespread adoption in the U.S. healthcare market.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Silicon Valley-based EBR Systems, Inc. is a company focused on the treatment of cardiac rhythm disease through its innovative wireless cardiac pacing technology. Their proprietary WiSE technology is designed to provide more effective cardiac stimulation by eliminating the need for traditional pacing leads, which are often associated with complications. The company’s initial product targets heart failure patients requiring Cardiac Resynchronisation Therapy (CRT) by stimulating the left ventricle without the need for coronary sinus leads.
Average Trading Volume: 997,192
For a thorough assessment of EBR stock, go to TipRanks’ Stock Analysis page.